Zobrazeno 1 - 9
of 9
pro vyhledávání: ''
Publikováno v:
Value in Health, 15(5), 604-612. Elsevier Science
Objectives: Medication nonadherence is common for osteoporosis, but its consequences have not been well described. This study aimed to quantify the clinical and economic impacts of poor adherence and to evaluate the potential cost-effectiveness of im
Autor:
A. Luque, M.R.C. Nobre
Publikováno v:
Value in Health. 16(7)
Publikováno v:
Value in Health. 16:A722-A723
Autor:
Susan E. Andrade
Publikováno v:
Value in Health. 1:171-173
Until 1994, rates of noncompliance for lipid-lowering therapies were largely drawn from clinical trials and showed favorable risks for drug discontinuation, ranging from 4–15% for 1-year risk to 11–30% for 5-year risk. Although cross-study compar
Autor:
Asha Hareendran, Mona L. Martin, Donald M. Bushnell, Holger J. Schünemann, Donald L. Patrick, C Gilbert
Publikováno v:
Value in Health. 9(6)
Publikováno v:
Value in Health. 16:A121-A122
Publikováno v:
Value in Health. 15:A173
Publikováno v:
Value in Health. 4:127-128
Health-related quality of life (HRQoL) research suggests that, due to unique characteristics of a disease state, disease specific tools are better discriminators of health status than generic tools. OBJECTIVE: To compare generic (SF-12) versus diseas
Autor:
Henry A. Glick, Bruce Kinosian
Publikováno v:
Value in Health. (3):181-185
Although a number of clinical trials are available estimating the benefits of lipid-lowering therapies that include economic end-points, development of modeling methodologies are essential to extend results of those trials over time and to other popu